Clinical Trial Update: Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A terminated Phase 1/2 clinical trial evaluating INCB007839 in combination with trastuzumab and vinorelbine for metastatic HER2-positive breast cancer, with rep…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• INCB007839 (INCB007839)
• Trastuzumab (trastuzumab)
• Vinorelbine (Vinorelbine)

Snippet

Sponsor: Incyte Corporation | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: TERMINATED